This inhibitor has been tested alone in NSCLC patients (NCT01193868) or in combination with agents targeting VEGFR (cediranib) or mTOR (temsirolimus) pathways in patients with solid tumors [161,162]. This evidence concerns the gene KDR and non-small cell lung carcinoma.